ESTRO 2024 - Abstract Book

S312

Brachytherapy - Head & neck, skin, eye

ESTRO 2024

for liquid, semi-solid and solid using Flexible Endoscopic Evaluation of Swallowing. The Mann-Whitney, Chi-Square and Fisher’s Exact Test was used for statistical analyses.

Results:

HyBIRT group has a better swallowing function compared to surgery in all 2 primary metric assessment: Swallowing Capacity Scale (SCS), a subjective scoring system to assess the severity of dysphagia (median score of 7 vs 4.5, p < 0.01). Another scoring system used is the Eating Assessment Tool (EAT-10) (fig 1) based on a set of 10 item questionnaire to assess the efficiency of swallowing (median score of 7 vs 19.5, p < 0.035). In the PAS (Penetration- Aspiration Scale) assessment, looking at aspiration risk during swallowing using three different concentrations of the swallowed materials which were liquid, semi-solid and solid. HyBIRT group was superior in PAS-liquid (median score 1 vs 2, p = 0.02), PAS-semi-solid (median score 1 vs 2, p = 0.022) but not statistically significant in PAS-solid (median score 1 vs 1, p = 0.264). While 25% of patients in PAS-solid were arrested at oral phase in the SG (vs 0% in HyBIRT), it did not reach statistical significance (p = 0.14). Two patients in the SG (vs 0% in HyBIRT) were nasogastric tube feeding dependent (p = 0.54).

Conclusion:

HyBIRT technique for definitive treatment of OTSCC in patients who are ineligible for surgery has shown a promising result which are at least equivalent to surgical series [3-year: LC rate, nodal control rate, OS and PFS of 94% (84% - 100%), 88% (73% - 100%), 61% (40% - 90%) and 68% (48% - 98%)] (1, 2). This current follow-up study showed a superior outcome in terms of swallowing function which is the major factor that contributes to poor QOL in OTSCC patients after cancer treatment. The shorter follow-up, smaller sample size in the HyBIRT group and non-stratified enrolment are the limitations of this study. A larger multicenter prospective trial of this hybrid method of upfront HDRIBT followed by IMRT (HyBIRT) with concurrent chemotherapy is needed to confirm the superior clinical outcomes in terms of disease control, OS and QOL as seen in both the earlier and this current study.

Keywords: swallowing, endoscopy, tongue

References:

Appalanaido G, Musa M, Chng E, Shukor SA, Chong S, Noor SM, et al. OC-0631 Upfront HDRIBT followed by IMRT for the Definitive Treatment of Tongue SCC. Radiotherapy and Oncology. 2023;182:S520-S1.

2. Gore SM, Crombie AK, Batstone MD, Clark JR. Concurrent chemoradiotherapy compared with surgery and adjuvant radiotherapy for oral cavity squamous cell carcinoma. Head & Neck. 2015;37(4):518-23.

2118

Digital Poster

Extra-Mammary Paget's Disease: Initial Experience with Custom 3D printed Surface Mould Brachytherapy

Amandeep S Taggar 1 , Moti R Paudel 2 , Dalal Assaad 3 , Elizabeth Barnes 1 , Michael Sidiropoulos 3